報價延遲最少15分鐘:2026/04/21 23:57 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.29 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.86/-1.17
|
|
企業價值
489.00M
|
| 資產負債 |
|
每股賬面淨值
3.33
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs. |
